大HBs抗原乙型肝炎疫苗中和具有疫苗逃逸突变的乙型肝炎病

StephenW

大HBs抗原乙型肝炎疫苗中和具有疫苗逃逸突变的乙型肝炎病毒

    石崎绫香、村山麻子、村田惠、清原智子、矢藤圭吾、山田典惠、侯赛因哈桑·阿里、田中智久、森石耕次、西藤博典、下野国忠、吴康正、石井健、四柳博、村松正通、石井浩二, Yoshimasa Takahashi, Ryosuke Suzuki, Hirofumi Akari & Takanobu Kato

Nature Communications第13卷，文章编号：5207（2022）引用本文

    1 高度计

    指标详情

抽象的

尽管目前包含小 HBs 抗原 (Ag) 的乙型肝炎 (HB) 疫苗是有效且安全的，但已经报道了针对具有疫苗逃逸突变 (VEM) 的乙型肝炎病毒 (HBV) 的减毒预防。我们研究了一种由大 HBsAg 组成的 HB 疫苗，它克服了当前 HB 疫苗的缺点。将酵母来源的大-HBsAg 免疫恒河猴，并将诱导抗体的中和活性与目前的HB 疫苗进行比较。尽管目前的 HB 疫苗诱导的抗体不能预防 VEM 对 HBV 的感染，但大 HBsAg 疫苗诱导的抗体可以中和这些感染。通过这些疫苗表现出减弱的中和作用的 HBV 基因型是不同的。在这里，我们表明由大 HBsAg 组成的 HB 疫苗有助于弥补当前 HB 疫苗的不足。这些 HB 疫苗的联合使用可能会诱导产生能够中和具有 VEM 或多种 HBV 基因型的 HBV 毒株的抗体。

StephenW

Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

    Ayaka Washizaki, Asako Murayama, Megumi Murata, Tomoko Kiyohara, Keigo Yato, Norie Yamada, Hussein Hassan Aly, Tomohisa Tanaka, Kohji Moriishi, Hironori Nishitsuji, Kunitada Shimotohno, Yasumasa Goh, Ken J. Ishii, Hiroshi Yotsuyanagi, Masamichi Muramatsu, Koji Ishii, Yoshimasa Takahashi, Ryosuke Suzuki, Hirofumi Akari & Takanobu Kato

Nature Communications volume 13, Article number: 5207 (2022) Cite this article

    1 Altmetric

    Metrics details

Abstract

Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.

StephenW

https://www.nature.com/articles/s41467-022-32910-z.pdf